Skip to main content
main-content

01.12.2012 | Case report | Ausgabe 1/2012 Open Access

Journal of Medical Case Reports 1/2012

Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report

Zeitschrift:
Journal of Medical Case Reports > Ausgabe 1/2012
Autoren:
Ester Simeone, Eleonora De Maio, Fabio Sandomenico, Franco Fulciniti, Secondo Lastoria, Pasquale Aprea, Stefania Staibano, Vincenzo Montesarchio, Giuseppe Palmieri, Nicola Mozzillo, Paolo A Ascierto
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1752-1947-6-131) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests, with the exception of PAA, who stood on the Advisory Board of Bristol Myers Squibb, Merck Sharp & Dohme, Roche-Genentech, GSK and Amgen and received honoraria from Bristol Myers Squibb, Merck Sharp & Dohme, Roche-Genentech; and SS, who received honoraria from Bristol Myers Squibb.

Authors’ contributions

ES, EDM, PA, VM and PAA performed all the clinical analyses. FF, SS and GP performed cytological and histopathological classifications. FS and SL performed the radiological and positron emission tomography scan evaluation. ES, EDM and GP helped to draft the manuscript. ES and NM participated in the design of the study. PAA conceived of the study and drafted the manuscript. All authors read and approved the final manuscript.

Abstract

Introduction

Leptomeningeal metastases are occurring at higher frequency in cancer patients. The prognosis of leptomeningeal metastases is poor and standard treatment, which includes radiotherapy and chemotherapy, is mostly ineffective. Melanoma represents one of the tumors with the highest incidence of leptomeningeal metastases. For such a disease, the BRAF inhibitors have recently been demonstrated to be effective on melanoma brain metastases harboring the V600EBRAF mutation.

Case presentation

We report a case of a 39-year-old Italian woman with advanced melanoma with brain, lung and peritoneum metastases harboring the V600EBRAF mutation. In August 2010 she was enrolled into the BRIM3 trial and after the randomization process she received dacarbazine. After two cycles, there was evidence of disease progression in her peritoneum and lung. For this reason, she was enrolled into another clinical trial with the GSK2118436 BRAF inhibitor, dabrafenib, as a second line of therapy. She had a partial response that was maintained until 13 weeks of treatment. In January 2011 she developed symptoms typical for brain metastases and received a diagnosis of leptomeningeal involvement of melanoma cells after an examination of her cerebral spinal fluid; magnetic resonance imaging was negative for meningitis or brain metastases. Analysis of her cerebral spinal fluid sample confirmed that the melanoma cells still carried the V600EBRAF mutation. After a few days, our patient went into a coma and died.

Conclusion

Starting with a clinical case, we discuss the pathogenesis of leptomeningeal metastases and whether the leptomeninges may represent a sanctuary where melanoma cells may generate resistance and/or BRAF inhibitors cannot reach an adequate concentration for significant activity. We assess whether treatment with BRAF inhibitors in melanoma patients should be interrupted as soon as disease progression appears or continued beyond progression, through the administration of additional compounds.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

e.Med Allgemeinmedizin

Kombi-Abonnement

Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.​​​​​​​​​​​​​​

Zusatzmaterial
Authors’ original file for figure 1
13256_2011_2154_MOESM1_ESM.pdf
Authors’ original file for figure 2
13256_2011_2154_MOESM2_ESM.pdf
Authors’ original file for figure 3
13256_2011_2154_MOESM3_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

Journal of Medical Case Reports 1/2012 Zur Ausgabe